Jatenzo Compounding Legal Status: FDA Approval, Label, and What It Means for Patients

FDA Approval History for Jatenzo

The FDA approved Jatenzo (NDA 206089) on March 27, 2019, making it the first oral testosterone undecanoate product cleared for use in the United States. The approval applied specifically to testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone [1].

A Long Road to Oral TRT Approval

Oral testosterone undecanoate had been available in Europe and Canada for decades under the brand name Andriol. The U.S. Approval took a different path. Clarus Therapeutics (now acquired by Tolmar) developed a novel self-emulsifying drug delivery system (SEDDS) formulation designed to improve lymphatic absorption and reduce first-pass hepatic metabolism, a known problem with older oral testosterone preparations [2].

The Key Trial: Swerdloff et al.

The approval rested primarily on a phase 3, open-label study published by Swerdloff and colleagues in the Journal of Clinical Endocrinology & Metabolism. In this trial (N=166), hypogonadal men received oral testosterone undecanoate 237 mg twice daily with food. At day 90, 87% of patients achieved average serum testosterone concentrations within the normal range (300 to 1,100 ng/dL). The Cavg for testosterone was 489 ng/dL across the study population [1].

Post-Approval Trajectory

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) at approval, a condition not imposed on injectable or transdermal testosterone products. This REMS requirement reflected safety signals around blood pressure elevation observed during clinical development. The product initially launched under Clarus Therapeutics before Tolmar acquired the asset. Tolmar continues to market and distribute Jatenzo under the existing REMS framework [3].

What the Jatenzo Prescribing Label Says

The Jatenzo label carries specific warnings and dosing instructions that distinguish it from other testosterone formulations. The prescribing information reflects a product the FDA views as carrying a somewhat different risk profile than injectable or topical testosterone.

Dosing and Administration

The recommended starting dose is 237 mg taken orally twice daily with food (474 mg total daily dose). Dose adjustments are permitted: the label allows titration down to 158 mg twice daily or up to 396 mg twice daily based on serum testosterone levels measured 6 hours post-dose after at least one week of treatment [3]. Food co-administration is not optional. Without fat-containing food, absorption drops significantly and therapeutic testosterone levels may not be reached.

Black Box Warning and Cardiovascular Signals

Jatenzo carries a boxed warning for blood pressure increases. In clinical trials, systolic blood pressure rose by a mean of 3 to 5 mmHg and diastolic by 2 to 3 mmHg compared to baseline. The label warns that these increases may raise the risk of major adverse cardiovascular events (MACE), including myocardial infarction and stroke [3]. This warning aligns with the broader FDA class-wide labeling change applied to all testosterone products in 2015, but Jatenzo received additional scrutiny due to the oral route and observed BP effects [4].

REMS Program Details

The Jatenzo REMS restricts distribution to certified pharmacies and requires prescribers to enroll in the program. Patients must have blood pressure assessed before starting treatment and monitored periodically during therapy. The REMS exists because the FDA determined that the benefits of Jatenzo could only outweigh its cardiovascular risks if specific safeguards were in place [3].

Hepatotoxicity Considerations

Unlike the older oral androgen methyltestosterone (17-alpha-alkylated), Jatenzo's testosterone undecanoate formulation is not 17-alpha-alkylated and is absorbed primarily through the lymphatic system. The label notes that hepatotoxicity has not been a significant signal in clinical trials, though liver function monitoring is still recommended as part of standard testosterone therapy management [1][3].

Compounding Legal Status Under Federal Law

Compounding copies of Jatenzo is not permitted under standard circumstances. This is the most consequential regulatory detail for patients exploring lower-cost alternatives to the branded product.

The 503A and 503B Framework

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), compounding pharmacies operate under two primary sections. Section 503A governs traditional compounding pharmacies that prepare medications based on individual prescriptions. Section 503B governs outsourcing facilities that can compound larger batches without patient-specific prescriptions but must register with the FDA and follow current Good Manufacturing Practices (cGMP) [5].

Both 503A and 503B pharmacies are prohibited from compounding drugs that are "essentially a copy" of a commercially available product. Because Jatenzo remains on the market and is not listed on the FDA's drug shortage list, compounding pharmacies cannot legally produce oral testosterone undecanoate capsules that replicate Jatenzo's formulation [5].

What "Essentially a Copy" Means in Practice

The FDA defines "essentially a copy" as a drug that is identical or nearly identical to an approved commercially available drug. A compounded oral testosterone undecanoate capsule using the same active ingredient, same route of administration, and comparable strength would meet this definition. The restriction applies regardless of whether the compounder uses an identical excipient profile [5].

There is one narrow exception: if a prescriber documents a clinical difference for an individual patient (such as an allergy to an inactive ingredient in the commercial product), a 503A pharmacy may compound a modified version. This exception requires a patient-specific prescription and a documented medical necessity that the commercial product cannot fulfill [5].

Testosterone Undecanoate as a Bulk Drug Substance

Testosterone undecanoate is listed in the United States Pharmacopeia (USP), which means it qualifies as a bulk drug substance available for compounding under certain conditions. The issue is not ingredient availability. The barrier is the "essentially a copy" prohibition when a commercially equivalent product exists. If Jatenzo were discontinued or placed on the FDA drug shortage list, the compounding field would shift immediately [6].

Schedule III Controlled Substance Implications

Jatenzo, like all testosterone products, is classified as a DEA Schedule III controlled substance under the Anabolic Steroids Control Act of 1990. Compounding pharmacies that handle testosterone must maintain DEA registration, follow controlled substance recordkeeping requirements, and comply with state-level regulations that may impose additional restrictions beyond federal law [7].

How Jatenzo Compares to Other Testosterone Products on Compounding Access

The compounding restrictions on Jatenzo stand in contrast to the widely available compounded injectable testosterone market. Understanding why requires examining the regulatory differences between formulations.

Injectable Testosterone: A Different Story

Testosterone cypionate and testosterone enanthate are available as FDA-approved products (Depo-Testosterone, Delatestryl), yet compounded versions of these injectables remain common. The reason: injectable testosterone has been on the FDA drug shortage list intermittently, and 503B outsourcing facilities received enforcement discretion from the FDA during those shortage periods. Even outside formal shortages, the FDA has historically exercised limited enforcement against compounded injectable testosterone given the scale of clinical demand [8].

Why Oral TU Is Different

Jatenzo's REMS program adds another layer of complexity. Compounding an oral testosterone undecanoate product that bypasses the REMS would undermine the FDA's risk management framework for this specific formulation. The REMS was imposed precisely because the oral route introduced blood pressure signals not seen at the same magnitude with injectable formulations. A compounder producing oral TU without REMS compliance would face regulatory action on two fronts: the "essentially a copy" prohibition and REMS circumvention [3][5].

The Kyzatrex Factor

Kyzatrex (oral testosterone undecanoate), approved by the FDA in 2022, represents a second commercially available oral testosterone undecanoate product. Its approval further solidifies the "commercially available" barrier against compounding. With two branded oral TU products on the market, the argument that a compounded version is necessary due to commercial unavailability has no regulatory footing [9].

Safety Profile and Post-Market Surveillance

Jatenzo's safety data extends beyond the key trial. Post-market surveillance and additional studies have filled in the risk profile that informs both the label and the REMS.

Cardiovascular Outcomes Data

The Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) trial (N=5,246) published in 2023 evaluated cardiovascular safety of transdermal testosterone gel versus placebo in hypogonadal men aged 45 to 80 with pre-existing cardiovascular disease or elevated risk. While TRAVERSE studied topical testosterone (not oral), the findings, showing non-inferiority on MACE at a hazard ratio of 0.96 (95% CI, 0.78 to 1.17), informed the broader testosterone safety discussion. The FDA cited TRAVERSE when updating class-wide testosterone labeling [10].

For Jatenzo specifically, the blood pressure signals remain the primary safety differentiator. In the key trial, mean systolic BP increased by 3.3 mmHg at day 105. Five percent of subjects developed systolic BP above 140 mmHg during treatment [1].

Polycythemia and Hematocrit Monitoring

Consistent with all testosterone formulations, Jatenzo can increase hematocrit levels. The label recommends checking hematocrit prior to treatment initiation, at 3 to 6 months, then annually. If hematocrit exceeds 54%, treatment should be stopped until the value decreases to an acceptable level [3]. In the Swerdloff trial, 4.8% of patients developed hematocrit values above 54% [1].

Liver Safety in Practice

Post-market pharmacovigilance data reported through the FDA Adverse Event Reporting System (FAERS) have not identified a hepatotoxicity signal for Jatenzo. This is consistent with the known pharmacology of testosterone undecanoate: lymphatic absorption bypasses first-pass liver metabolism, reducing hepatic exposure compared to 17-alpha-alkylated oral androgens like methyltestosterone or oxandrolone [2][3].

What Patients and Clinicians Should Know Right Now

The practical implications of Jatenzo's regulatory status affect prescribing decisions, cost considerations, and patient access.

Cost and Insurance Reality

Jatenzo's wholesale acquisition cost (WAC) places it among the more expensive testosterone replacement options. Without insurance, cash prices can exceed $500 per month. The REMS-restricted distribution means patients cannot fill prescriptions at every retail pharmacy, further limiting convenience. Tolmar offers a patient savings program, but eligibility requirements and coverage gaps vary [3].

When Compounding Might Become Available

Two scenarios would open the door to legal compounding of oral testosterone undecanoate: (1) Jatenzo and Kyzatrex both being discontinued or withdrawn from the market, or (2) the FDA placing oral testosterone undecanoate on the official drug shortage list. Neither scenario appears imminent as of May 2026. Patients who require oral testosterone and cannot afford or tolerate Jatenzo should discuss alternative TRT routes (injectable, transdermal, nasal, or subcutaneous pellet) with their prescriber [5][8].

State-Level Variability

Some states impose compounding regulations stricter than federal law. A few states have interpreted "essentially a copy" provisions more broadly or have additional restrictions on compounding controlled substances. Patients should confirm both federal and state-level legality with their compounding pharmacy before assuming a testosterone product can be prepared [7].

Clinicians prescribing Jatenzo should ensure enrollment in the REMS program, verify pharmacy certification, and monitor blood pressure at baseline and at each follow-up visit per the label's risk management requirements [3].